Rahman A, Korzekwa K R, Grogan J, Gonzalez F J, Harris J W
Division of Biopharmaceutics, United States Food and Drug Administration, Rockville, Maryland 20857.
Cancer Res. 1994 Nov 1;54(21):5543-6.
The principal taxol biotransformation reaction of humans and of human hepatic in vitro preparations is 6 alpha-hydroxylation of the taxane ring, but a separate, minor hydroxylation pathway (metabolite B formation) also exists. Taxol metabolism was studied using membrane fractions from Hep G2 cells infected with recombinant vaccinia viruses that contain complementary DNAs encoding several human cytochrome P450 enzymes. Only P450 2C8 formed detectable 6 alpha-hydroxytaxol. Metabolite B formation was catalyzed by complementary DNA-expressed 3A3 and 3A4, but not by 3A5. Each P450 3A preparation catalyzed felodipine oxidation. The apparent Km and Vmax values for taxol 6 alpha-hydroxylation were 5.4 +/- 1.0 microM and 30 +/- 1.5 nmol/min/nmol P450, respectively, for complementary DNA-expressed P450 2C8; the values were 4.0 +/- 1.0 microM and 0.87 +/- 0.06 nmol/min/mg protein, respectively, for human hepatic microsomes. The inhibition of 6 alpha-hydroxytaxol formation by quercetin was competitive with an apparent Ki of 1.3 or 1.1 microM with 2C8 or hepatic microsomes, respectively; retinoic acid was inhibitory, showing an apparent Ki of 27 microM with hepatic microsomes; inhibition by tolbutamide was complex, weak, and unlikely to be clinically relevant. The correlation between hepatic 2C8 protein content and 6 alpha-hydroxytaxol formation was high (r2 = 0.82), while the correlation with 2C9 content was low (r2 = 0.38). These data show that human biotransformation routes of taxol result from catalysis by specific enzymes of two P450 families and that taxol 6 alpha-hydroxylation is a useful indicator of P450 2C8 activity in human hepatic microsomes.
人类及人肝脏体外制剂中主要的紫杉醇生物转化反应是紫杉烷环的6α-羟基化,但还存在一条独立的、次要的羟基化途径(代谢物B的形成)。使用感染了重组痘苗病毒的Hep G2细胞的膜组分研究紫杉醇代谢,这些重组痘苗病毒含有编码几种人细胞色素P450酶的互补DNA。只有P450 2C8能形成可检测到的6α-羟基紫杉醇。代谢物B的形成由互补DNA表达的3A3和3A4催化,但3A5无此催化作用。每种P450 3A制剂都能催化非洛地平氧化。对于互补DNA表达的P450 2C8,紫杉醇6α-羟基化的表观Km和Vmax值分别为5.4±1.0微摩尔和30±1.5纳摩尔/分钟/纳摩尔P450;对于人肝脏微粒体,其值分别为4.0±1.0微摩尔和0.87±0.06纳摩尔/分钟/毫克蛋白。槲皮素对6α-羟基紫杉醇形成的抑制作用具有竞争性,对2C8或肝脏微粒体的表观Ki分别为1.3或1.1微摩尔;视黄酸具有抑制作用,对肝脏微粒体的表观Ki为27微摩尔;甲苯磺丁脲的抑制作用复杂、微弱,且不太可能具有临床相关性。肝脏2C8蛋白含量与6α-羟基紫杉醇形成之间的相关性较高(r2 = 0.82),而与2C9含量的相关性较低(r2 = 0.38)。这些数据表明,紫杉醇的人体生物转化途径是由两个P450家族的特定酶催化产生的,并且紫杉醇6α-羟基化是人类肝脏微粒体中P450 2C8活性的一个有用指标。